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Abstract
Objectives Stereotactic body radiotherapy (SBRT) is a defin-
itive local treatment option for patients with stage I non-small
cell lung cancer (NSCLC) who are not surgical candidates and
patients who refuse surgery. The purpose of this study was to
assess the impact of SBRTon T1–T2 NSCLC from a national
registry, reflecting practices and outcomes in a real-world
setting.
Methods The RSSearch® Patient Registry was screened for
T1–T2N0M0NSCLC patients treated fromMay 2004 toMay
2013 with SBRT. Descriptive analyses were used for patient,
tumor, and treatment characteristics. Overall survival (OS)
and local control (LC) were calculated using the Kaplan-
Meier method.
Results In total, 723 patients with 517 T1 and 224 T2 lesions
were treated with SBRT. Median follow-up was 12 months
(1–87 months) with a median age of 76 years. Median SBRT
dose was 54 Gy (range 10–80 Gy) delivered in a median of 3
fractions (range 1–5), and median biological equivalent dose
(BED10) was 151.2 Gy (range 20–240 Gy). Median OS was
30 and 26 months for T1 and T2 tumors, respectively (p=
0.019). LC was associated with higher BED10 for T2 tumors,
but not in T1 tumors at a median follow-up of 17 months.
Seventeen-month LC for T2 tumors treated with BED10<
105 Gy, BED10 105-149, and BED10≥150 Gy was 43, 74,
and 95 %, respectively (p=0.011). Local failure rates for T2
tumors treated with BED10<105 Gy, 105–149 Gy, and
≥150 Gy were 32, 21, and 8 % (p=0.029), respectively.
J. N. Davis












Department of Radiation Oncology, Medstar Franklin Square
Medical Center, Baltimore, MD, USA
e-mail: David.James.Perry@medstar.net
J. Pablo




Department of Radiation Oncology, New Jersey CyberKnife at
Community Medical Center, Toms River, NJ, USA
e-mail: DDAmbrosio@barnabashealth.org
H. McKellar












Department of Radiation Oncology, Beth Israel Deaconess Medical
Center, Harvard Medical School, Boston, MA, USA
e-mail: amahadev@bidmc.harvard.edu
J Radiat Oncol (2015) 4:55–63
DOI 10.1007/s13566-014-0177-0
Median OS for patients with T2 tumors treated with BED10<
105 Gy was 17 vs. 32 months for T2 tumors treated with
BED10 105–149 Gy (p=0.062).
Conclusion SBRT for T1–T2NSCLC is feasible and effective
in the community setting. OS was greater for patients with T1
lesions compared to T2 lesions. An improvement in LC was
observed in patients with T2 lesions treated with BED10>
105 Gy.
Keywords Stereotactic body radiotherapy . Lung cancer .
Non-small cell lung cancer . Registry . Radiosurgery
Introduction
The standard treatment for patients with stage I (IA and IB)
non-small cell lung cancer (NSCLC) with no medical contra-
indication is surgery. Surgery results in a loco-regional control
rate of 90 % and a 5-year overall survival rate of 50–70 % for
stage I NSCLC [1]. A significant number of early-stage lung
cancer patients have co-morbidities which make them unsuit-
able for curative surgery. Radiation therapy is an alternative
treatment for medically inoperable patients or patients who
refuse surgery; however, conventional radiation therapy using
60 to 70 Gy results in relatively poor local control (30–70 %)
and survival (15–30 %) [2, 3]. Stereotactic body radiotherapy
(SBRT) is a form of ablative radiation therapy which delivers
high doses of radiation in fewer fractions compared to con-
ventional radiation therapy. At the same time, SBRT allows to
minimize the dose to surrounding the normal lung, often dis-
eased in this population, making them poor candidates for
surgery in the first place. Studies show that SBRT improves
local control rates of early-stage NSCLC with a local control
rate of 85–98 % and 3-year overall survival rate of 48–65 %
[4–13]. SBRT has been shown to reduce local recurrence in
borderline surgical candidates with early-stage I NSCLC com-
pared to limited resection [14–16]. SBRT is now considered a
standard treatment for inoperable stage I NSCLC and is
being explored as a treatment option for medically op-
erable patients [17]. However, the optimal treatment and
schedule of SBRT for T1–T2N0M0 lung cancer are still
being explored.
Based on available evidence, technical capability exists to
perform SBRT in the community setting and is being routinely
done. As the role for SBRT to treat NSCLC expands in con-
trolled prospective clinical trials, it will be important to under-
stand how SBRT is being implemented in the community
setting and to investigate the clinical outcomes. Patient regis-
tries can be powerful tools to describe treatment management
patterns, understand variations in treatment and outcomes,
study generalizability of clinical trial results, and can comple-
ment data from randomized clinical trials. Another potential
benefit of a registry is that data for patient demographics,
treatment practices, and outcomes can be captured from a
large number of patients rapidly. The RSSearch® Patient Reg-
istry was designed to standardize data collection for patients
treated with SRS and SBRT and currently includes
screening, treatment, and outcome data for over 14,000
patients treated with SRS/SBRT [18]. The purpose of
this study was to examine disease presentation, treat-
ment practices, and clinical outcomes of patients with
T1–T2N0M0 NSCLC enrolled in RSSearch®, thereby
producing a real-world picture of disease, current treat-
ment practices, and outcomes in radiation therapy using
SBRT.
Methods
A retrospective analysis of patients with histologically proven
T1–T2N0M0 NSCLC treated with SBRT and enrolled in the
RSSearch® Pat ien t Reg is t ry (Cl in ica l t r i a l s .gov
Identifier:NCT01885299) was performed. The RSSearch®
Patient Registry is managed by the Radiosurgery Society, a
non-profit professional medical society. A description of the
methodology, database design, and initial patient and treat-
ment characteristics of patients enrolled in RSSearch® has
been previously reported [18]. The database is housed by an
independent third party, AdvertekSM (Louisville, KY), and
meets all requirements to comply with the Health Insurance
Portability and Accountability Act and Safe Harbor Policy to
maintain system security, transmission of data, and patient
confidentiality. All centers treating patients with SRS/SBRT
clinically are offered and encouraged to participate in
RSSearch®. Participation is voluntary, and no compensation
is provided either to patients or participating centers. Each
principal investigator is provided a copy of the RSSearch®
Registry protocol, case report forms, sample patient informed
consent, and web-based training for data entry and database
navigation. Institutional Review Board (IRB) approval is re-
quired at all participating centers. All procedures followed
were in accordance with the ethical standards of the responsi-
ble committee on human experimentation (institutional and
national) and with the Helsinki Declaration of 1975, as revised
in 2008 (5). All patients who are screened for potential SRS/
SBRT treatment are eligible to be included in the RSSearch®
Registry. Informed consent was obtained from all patients, as
required by individual IRBs, prior to the patient’s data entered
into the RSSearch® Registry. Retrospective analysis of
RSSearch® is conducted from prospectively entered data.
The selection of centers for this study included RSSearch®
participating centers that treated NSCLC patients with SBRT
between May 2004 and May 2013, with complete data entry
fields for screening, treatment, and follow-up (minimum sur-
vival data) for their respective patients. For this analysis,
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NSCLC patients were treated at 14 institutions within the
USA. Each center followed an independent Institutional Re-
view Board (IRB)-approved protocol for RSSearch®
participation.
Patients were treated with SBRT according to institutional
guidelines. To compare the effects of various treatment proto-
cols with different treatment fraction sizes and doses, the bio-
logical equivalent dose (BED) was calculated using the linear
quadratic model, as BED=D × (1+d/α/β) whereD is the total
dose, d is the dose per fraction, and the α/β ratio for
the tumor was 10 Gy. Normal tissue dose restraints
were reported by the treating institutions and captured
in RSSearch® as the maximum point dose and inter-
quartile range for each structure.
Patient follow-up was performed per institutional guide-
lines. All participating centers reported follow-up clinical
and imaging data. Local control was evaluated independently
for each lesion at the participating institution following a mod-
ified Response Evaluation and Criteria in Solid Tumors
(RECIST) criteria. Lesion response was graded as either com-
plete response (CR) defined as disappearance of all lesion/s
treated, partial response (PR) defined as reduction in lesion
size of lesions treated in by 30 % or greater, and stable disease
(SD) defined as neither sufficient shrinkage nor sufficient in-
crease of size of lesions. Local progression was defined as at
least a 20 % increase in the size of lesions and/or appearance
of one or more lesions in target treatment location and
local control (LC) defined as disappearance of, decrease
in, or no increase in size of the treated lesions. Analy-
ses of LC, DC, and OS were calculated using the
Kaplan-Meier method. LC was analyzed for each treated
tumor whereas analysis of DC and OS was calculated
for every patient. Specific cause of death was not re-
ported for all patients in RSSearch® and therefore not
evaluated in this study. Subgroups were compared using
X2 and log-rank statistics. Values of p<0.05 were con-
sidered statistically significant. Statistical calculations
were conducted using Instat and GraphPad Prism (La
Jolla, CA).
Results
Demographics and lesion characteristics
In total, 723 patients with 741 lesions diagnosed with T1–T2
primary NSCLC lung cancer between May 2004 and May
2013were included in this study. Themedian agewas 76 years
(range 41–95 years), 52 % were female and 48 % were male
(Table 1); 88 % were Caucasian, 6 % African-American, and
0.7 % Hispanic. The median Karnofsky Performance Score
was 80 (range 40–100). Three hundred seventy-four patients
(52 %) were considered medically inoperable, 111 patients
(15 %) were surgically inoperable, and the rest refused sur-
gery. The primary co-morbidities for medically inoperable
patients included pulmonary (n=258), cardiac (n=66), vascu-
lar (n=9), and advanced age with poor performance status (n=
6). Eighty-four percent of patients had no prior treatment, 9 %
had received chemotherapy, 2 % had undergone surgery, and
1 % had received external beam radiation therapy. Patients
were most commonly referred to the radiation oncology de-
partment for SBRT evaluation by medical oncology (37 %),
followed by pulmonology (21 %), cardio-thoracic surgery
(17 %), other radiation oncology (10 %) departments, and
self-referral (3 %). Medicare was listed as the primary payer
for 72 % of patients, private insurance for 17 %, Medicaid for
2 %, Veterans Administration for 2 %, and uninsured/self-pay
for 1 patient.
The lesion characteristics are shown in Table 2. Seventy
percent of lesions were T1 (n=517) and 30 % were T2 (n=
224). The median lesion volume was 14.9 cc, and the median
maximal tumor diameter was 2.4 cm (range 0.2–6.5 cm).
Twenty-four patients had more than one lung tumor treated
with SBRT (range 1–4 lesions). Pathological diagnosis was
completed for all patients, and the histological subtypes were
reported as adenocarcinoma (n=248), NSCLC (n=238),
Table 1 Patient characteristics and demographics
Variable Number
Gender: n=723 patients
Male 349 (48 %)
Female 374 (52 %)
Median age in years (range) 76 (41–95)
Median weight in lbs (range) 160 (60–330)
Median Karnofsky performance score (range) 80 (40–100)
Median VAS Pain Score (range) 0 (0–9)
Current or previous smoker 630 (87 %)
Median smoker pack/years (range) 50 (1–545)
Race/ethnicity
Caucasian 634 (88 %)
Black/African American 42 (6 %)
Hispanic 5 (0.7 %)
Other 2 (0.3 %)
Unknown 39 (5 %)
Medically inoperable 374 (52 %)
Surgically inoperable 111 (15 %)
Prior Treatment(s): n=741 lesions
None 622 (84 %)
Chemotherapy 69 (9 %)
Surgery 17 (2 %)
External beam radiation 9 (1 %)
Radiosurgery 3 (0.4 %)
Radiofrequency ablation 3 (0.4 %)
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squamous cell carcinoma (n=224), bronchiolo-alveolar carci-
noma (n=15), and large cell carcinoma (n=16).
SBRT treatment
SBRT was indicated as the primary treatment for 91 % (n=
675) of lesions and adjuvant treatment for 8 % (n=61) lesions.
Treatment indication was not reported for five patients. The
most common SBRT dose-fractionation schedules are shown
in Table 2 and include 60 Gy in 3 fractions (n=219), 54 Gy in
3 fractions (n=162), 50 Gy in 5 fractions (n=79), 50 Gy in 4
fractions (n=78), and 48 Gy in 4 fractions (n=45). The medi-
an dose was 54 Gy delivered in 3 fractions, and the median
BED10 was 151.2 Gy (range, 20–240 Gy). The median
maximum point dose (Dmax) to the target was 72.7 Gy
(range 10–113 Gy).
Doses to organs at risk (OAR) were reported in RSSearch®
as the Dmax for each individual OAR. Table 3 shows the
median Dmax (range, 25th percentile and 75th percentile)
for the esophagus, brachial plexus, trachea, main bronchus,
heart, major vessels, and spinal cord. The median Dmax for
esophagus, brachial plexus, trachea, main bronchus, heart,
major vessels, and spinal cord were 9.9, 18.6, 13.5, 14.5,
12.5, 18.3, and 7.2 Gy, respectively. For comparison, the dose
tolerance limits are also shown for Radiation Therapy Oncol-
ogy Group (RTOG) 0236 protocol for medically inoperable
patients treated with 54 Gy delivered in 3 fractions [7]. For all
OARs, the dose reported at the 75th percentile was below the
maximum dose limits specified in RTOG 0236.
Overall survival (OS), local control (LC), and distant disease
control (DC)
The median follow-up was 12 months (range 1–87 months).
Kaplan-Meier curves for survival are shown in Fig. 1. The
median OS for the entire group was 29 months (95 % CI,
23–34 months). The median OS of patients with T1 and T2
tumors was 30 and 26 months, respectively (p=0.019;
Fig. 1a). One-year OS was 85 % (95 % CI, 81–88 %) for T1
and 76 % (95 % CI, 68–81 %) for T2 tumors. The 2-year OS
rate was 63 % (95 % CI, 56–69 %) for T1 and 52 % (95 % CI,
42–60 %) for T2 tumors.
Four hundred and thirty-four lesions from 429 patients
were evaluated for tumor response. A reduction in tumor size
Table 2 Lesion and SBRT treatment characteristics
Variable Number
T1N0M0 517 (70 %)
T2N0M0 224 (30 %)
Histology:
Adenocarcinoma 248 (33 %)
Non-small cell carcinoma 238 (32 %)
Squamous cell carcinoma 224 (30 %)
Large cell carcinoma 16 (2 %)
Bronchiolo-alveolar carcinoma 15 (2 %)
Median lesion volume, cc (range) 14.9 (0.5–334)
Median lesion size, long axis, cm (range) 2.4 (0.2–6.5)
Lesion location
Right upper lobe 197 (27 %)
Right middle lobe 38 (5 %)
Right lower lobe 116 (16 %)
Right lobe, NOS 5 (2 %)
Left upper lobe 185 (25 %)
Left middle lobe 13 (2 %)
Left lower lobe 94 (13 %)
Left lobe, NOS 9 (1 %)
Bronchus 3 (0.4 %)
Not indicated 81 (11 %)
Median SBRT dose (range), Gy 54 (10–80)
Median number of fractions 3 (1–5)
Median BED10 dose, Gy 151.2 (2–240)
Most common dose/fraction schemes:
20 Gy×3=60 Gy 219 (30 %)
18 Gy×3=54 Gy 162 (22 %)
10 Gy×5=50 Gy 79 (11 %)
12.5 Gy×4=50 Gy 78 (11 %)
12 Gy×4=48 Gy 45 (6 %)
12 Gy×5=60 Gy 25 (3 %)
Median Dmax (range), Gy 72.7 (10–113)
Median monitor units 39,373 (5614–102,565)
Table 3 Doses to normal adjacent structures
Organ Dmax, 25th Percentile (Gy) Median Dmax (range) Dmax, 75th Percentile (Gy) Max dose constraints, RTOG 0236 [7]
Esophagus 6 9.9 Gy (0–51.1) 16 27 Gy max
Brachial plexus 4 18.6 Gy (0.02–43.5) 23.5 24 Gy max
Trachea 7 13.5 Gy (0–64.9) 26 30 Gy max
Main bronchus 8 14.5 Gy (0–63.0) 28 30 Gy max
Heart 7 12.5 Gy (0–96) 20 30 Gy max
Major vessels 10 18.3 (0.1–64) 34 39 Gy
Spinal cord 4.5 7.2 (0–75) 11.8 18 Gy
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was reported in 254 lesions (59 %) with a complete response
reported in 131 lesions and partial response reported in 123
lesions. Stable disease was reported in 62 (14 %) lesions.
Local failure was reported in 57 lesions (13 %). One-year
LC was 88 % (95 % CI, 84–92 %) and 2-year LC was 76 %
(95 % CI, 68–82 %). When stratified by T-classification, 1-
year LCwas 89% (95%CI, 84–93%) for T1 and 85% (95%
CI, 74–91 %) for T2 tumors (Fig. 1b). The median time to
local failure was 54 and 47 months for T1 and T2 tumors,
respectively (p=0.178). Seventy-six patients were reported
to have distant disease progression. One-year DC was 85 %
(95 % CI, 80–89 %) and 78 % (95 % CI, 68–86%) for T1 and
T2 tumors, respectively (Fig. 1c).
BED10 was calculated for each dose/fractionation regimen,
and LC and OS were assessed for patients who received
BED10<105 Gy vs. BED10 105–149 Gy vs. BED10≥
150 Gy. Local failure was associated with lower BED10 for
T2 lesions. Local failure occurred in 32 % of patients treated
with BED10<105 Gy vs. 21% for BED10 105–149 Gy vs. 8%
for BED10≥150 Gy (p=0.029 by X2 test; Table 4). Median
time to local failure was 17 months for T2 tumors treated with
BED10<105 Gy and not reached for BED10≥105. The 17-
month LC rate was 43 % (95 % CI, 15–71 %) for BED10<
105 Gy, 74 % (95 % CI, 50–88 %) for BED10 105–149 Gy,
and 95 % (95 % CI, 81–99 %) for BED10≥150 Gy (p=0.011;
Fig. 2a). There was no difference in local failure rates for T1
tumors treated with the different BED10 doses. Local failure
was reported in 15 % of T1 lesions treated with BED10<
105 Gy, 11 % for BED10 105–149 Gy, and 11 % for
BED10≥150 Gy (p=0.713 by X2; Table 4). The 1-year LC
rate for T1 lesions was 84 % (95 % CI, 69–92 %) for
BED10<105 Gy, 85 % (95 % CI, 71–93 %) for BED10 105–
149 Gy, and 93 % (95 % CI, 87–97 %) for BED10≥150 Gy
(Fig. 2c).
For patients with T2 lesions treated with BED10>105 Gy,
there was a trend for improved OS, although it did not reach
statistical significance. The 1-year OS rate for T2 lesions treat-
ed with BED10<105 Gy, BED10 105–149 Gy, and BED10≥
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Fig. 1 Survival curves for T1 and T2 lesions treated with SBRT. Kaplan-
Meier analysis of overall survival (a), local control (b), and distant disease
control (c) for patients with T1 (solid lines) and T2 (dotted lines) NSCLC
treated with SBRT. Ticked marks indicate censored patients. Patients with
T1 lesions had greater overall survival compared to T2 lesions (p=0.019
by log-rank test)
Table 4 Local failures for T1 and T2 tumors stratified by BED10
T stage BED<105 Gy BED 105–149 Gy BED≥150 Gy p value
(X2 test)
T1 8/55 (15 %) 10/92 (11 %) 18/170 (11 %) 0.713
T2 8/25 (32 %) 9/42 (21 %) 4/50 (8 %) 0.029a
a Indicates statistically significant value
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150 Gy was 63 % (95 % CI, 49–76 %), 78 % (95 % CI, 65–
86 %), and 81 % (95 % CI, 69–88 %), respectively. Median
OSwas 17 vs. 28months for BED10<105 Gy vs. BED10 105–
149 Gy (p=0.062; Fig. 2b). There was no further improve-
ment of OS for T2 lesions treated with BED10≥150 Gy com-
pared to BED10 105–149 Gy (p=0.62). Increasing BED10
was not associated with improved OS for T1 lesions. Median
OS for patients with T1 lesions was 30, 33, and 30 months
(p=0.710) treated with BED10<105 Gy vs. BED10 105 –
149 Gy vs. BED10≥150 Gy, respectively (Fig. 2d).
Discussion
This study reports on the initial analysis of SBRT treatment of
T1–T2 NSCLC from patients enrolled in the RSSearch® Pa-
tient Registry, the largest registry dedicated to SRS/SBRT
treatment managed by a non-profit medical society. The goal
of the current analysis was to evaluate the current manage-
ment practices and outcomes of SBRT for early-stage lung
cancer in a real-world setting. Our results demonstrate that
participating centers are adhering to recommended treatment
guidelines and published reports for SBRT treatment of T1–
T2 lung cancer. The LC and OS rates reported in this study are
in line with previous published reports of single institution,
retrospective, and prospective studies [4, 5, 7–10, 12, 13,
19–21].
We acknowledge that this study is an observational study
and that only randomized controlled clinical trials can conclu-
sively determine survival benefits and differences in outcomes
from treatment parameters; however, no such comparative
efficacy or dose-escalation studies or data currently exist for
SBRT for early-stage lung cancer. In the absence of this data,
patient registries can provide important information to identify
new treatment regimens, identify patients that may be most
beneficial to treatments, generate new hypotheses on dose-
response and response assessment, and thereby complement
Fig. 2 Local control (LC) and overall survival (OS) for T1 and T2
lesions treated with BED10<105 Gy vs. 105-149 Gy vs. ≥150 Gy.
Kaplan-Meier analysis of LC for T2 (a) and T1 (c) lesions and OS for
T2 (b) and T1 (d) lesions treated with BED10<105 Gy (dotted line),
BED10 105–149 (dashed line), and BED10≥150 Gy (solid line). Tick
marks indicate censored patients. LC improved for T2 lesions treated with
BED10 (p=0.011 by log-rank test), but not T1 lesions. There was a trend
for improved OS for T2 lesions treated with BED10105–149 compared to
BED10<105 although it did not reach statistical significance (p=0.062
by log-rank test)
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randomized clinical trials. In this study, we identified im-
proved LC and improved OS in patients with T2 lesions treat-
ed with SBRT doses of BED10>105 Gy. Evidence exists for a
dose-response relationship with standard fractionated radio-
therapy and stage I NSCLC [22, 23]. Published results on
dose-response relationships with SBRT and stages I–II
NSCLC have been limited and controversial. Onishi et al.
reported improved LC and OS in 257 patients with BED≥
100 Gy compared to BED<100 Gy [6]. Grills et al. reported
that BED10 predicted local relapse and distant metastasis in
patients with T1–T3 N0M0 NSCLC with a 2-year local re-
lapse of 15 % for BED10<105 Gy vs. 4 % for BED10≥105
[5]; however, BED10 dose relationships to local relapse were
not stratified by T-classification in this study. In contrast,
Stephans et al. did not find improvement for OS, LC, nodal
failure, or distant metastasis in patients who received 60 Gy in
3 fractions (BED10=180 Gy) compared to patients who re-
ceived 50 Gy in 5 fractions (BED10=100 Gy); however, the
follow-up was limited with a median of 9.5 months (range
2.1–19.5 months) for patients (n=38) that received 60 Gy in
3 fractions [24]. In our current study, the median time to local
failure for T2 lesions with BED10<105Gywas 17months and
not met for BED10>105 Gy, suggesting that follow-up longer
than 17months is needed to detect differences between BED<
105 vs. >105 Gy. Several studies using CyberKnife Robotic
Radiosurgery System have reported a dose response for LC of
early-stage lung cancer [21, 25, 26]. Le et al. reported 1-year
LC rate of 91 % for patients treated with a single fraction of
greater than 20 Gy vs. 54 % for patients who received a single
fraction of less than 20Gy [25]. Nuyttens et al. reported 2-year
LC rate of 85% for patients with centrally located tumors who
received BED>100 Gy (60 Gy delivered in 5 fractions) vs.
60 % for patients who received BED≤100 Gy (45–50 Gy
delivered in 5 fractions) [26]. van der Voort van Zyp et al.
reported a 95 % LC for stage I patients who received
60 Gy delivered in 3 fractions vs. 78 % for patients
who received 45 Gy delivered in 3 fractions [21]. In
these studies, the effect of dose on T1 vs. T2 tumors
was not studied. Onimaru et al. reported improved LC
and OS in IB tumors treated to 48 Gy compared to
40 Gy delivered in four fractions, but did not find a
response in IA lesions and suggested dose-response re-
lationships may be related to tumor size [27].
There are several limitations of this study. First, as is com-
mon to registries, the patient inclusion criteria are not exclu-
sively defined and the patient cohort represents a heteroge-
neous population. Our cohort included tumor sizes up to
6.5 cm, including an assortment of peripheral and centrally
located tumors. Patients were also treated with a wide range
of dose/fractionation schemes. Despite these variations, the
LC rate in our study was 90 % and higher for T1 and T2
lesions treated with BED>150 Gy and in line with previously
published reports [5, 21, 25, 26, 28].
Another limitation of multi-institutional registries is
obtaining complete follow-up information. While the majority
of follow-up information was available, not all patients’ tumor
response assessment was reported. Also, evaluation of recur-
rence did not require histological confirmation and relied on
non-invasive tests including CT and PET. This is not uncom-
mon in routine clinical practice. More importantly, this study
did not report on toxicities consistently at this time and the
causes of death are not always recorded. As this and other
registries continue to mature, these aspects will be addressed
and future studies on acute and late toxicities will be reported.
Further long-term follow-up is warranted to determine wheth-
er the outcomes observed in this initial report will persist at
5 years and beyond.
Although SBRT for stage I lung cancer has been available
for several years, there are continuous improvements in tech-
nology and expansion of indications for SBRT lung treat-
ments. The RSSearch® Patient Registry continues to capture
patient data, reflecting the treatment patterns and clinical out-
comes from the real world. An advantage of patient registries
is the ability to capture data on a large number of patients in a
short time and report on outcomes rapidly. When information
capture, including patient and treatment characteristics and
follow-up data including response assessment and toxicity is
done more rigorously, such studies could complement and
validate results from randomized studies. Moreover, this
may be a robust avenue to study applicability and generaliz-
ability of randomized clinical trials in the real-world commu-
nity setting.
Conclusions
We report on one of the largest multi-center datasets of early-
stage NSCLC patients treated with SBRT and report on the
current treatment management practices and outcomes in the
community. Registries are useful tools to assess management
practices and outcomes in the real world. Local control and
survival outcomes for stage I NSCLC are not dissimilar to
single institutional and prospective studies. Additionally, an
improvement in LC was observed in patients with T2 lesions
treated with BED10>105 Gy, supporting a dose response,
which was not seen in patients with T1 lesions.
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